NAD+review2026

Enzymatic and Chemical Synthesis for ADP-Ribosylation Using NAD+ as Building Blocks: New Concerns in Reaction Discovery and Design.

Chembiochem : a European journal of chemical biology

confidence

Key findings

Review of enzymatic and chemical synthesis methods for ADP-ribosylation using NAD+ as a building block; no clinical or biological endpoints reported.

View source on PubMed (PMID 41816858) ↗

Sample size
N/A
Population
Not applicable (review article on synthesis methods)
Dosing
N/A
Duration
N/A
Route
N/A
Blinding
not_reported
Controls
not_reported
Drug class
coenzyme
Full abstract

Nicotinamide adenine dinucleotide (NAD+), as an endogenous donor for ADP-ribosylation, can modify DNA, RNA, and proteins, thereby participating in the regulation of the functions of these biomacromolecules. NAD+ serves as a reactant in both enzymatic and chemical synthesis. By employing a well-designed reaction process, the synthetic route can be significantly streamlined, enabling the preparation of structurally complex bioactive molecules in a step-saving and highly effective manner. This article reviews the latest research progress in this field. In the field of enzymatic synthesis, a strategy based on the HPF1/PARP1 complex has been developed. Earlier study shows that the recombinant HPF1/PARP1 complex can ADP-ribosylate a variety of substrates in vitro. In the field of chemical synthesis, the focus is on ionic liquid-mediated ADP-ribosylation reactions with controllable α/β configurations of products. These reactions help prepare biologically active ADP-ribosylated (ADPr) peptides from NAD+ and commercially available peptides. In addition, this article also outlines the applications of functional NAD+ derivatives in enzyme activity analysis and inhibitor development and discusses the challenges faced in this field, such as bio-compatible reaction conditions, synthesis for precise structural control, and structure-activity relationships between stereochemistry and biological functions of more ADPr derivatives.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.